WHAT: Cardiology experts from Canada and around the world converge in Vancouver to brainstorm strategies to eradicate the impact of heart disease, showcase the latest research breakthroughs − and hear hundreds of speakers highlight innovations in science, prevention, treatment, and recovery. Congress delegates return home to their labs and practices armed with new tools and knowledge that will help prevent heart disease and save lives.
WHY: Heart disease is a leading cause of hospitalization and the second leading cause of death in Canada. Every seven minutes in Canada, someone dies from heart disease or stroke. Over 1.3 million survivors − and their families and caregivers − are living with the devastating after effects of heart disease. Millions of Canadians are at risk.
WHERE: Vancouver Convention Centre in Vancouver, BC
WHEN: Interviews available now through Oct 24, including onsite in Vancouver from Oct. 21 to 24
INTERVIEW OPPORTUNITIES:
- Leading heart experts: Available to talk about the impact of heart disease, why it matters to all Canadians, and give highlights of the research discoveries and innovations being presented at the 2017 Congress.
- Congress researchers and presenters: The presenters featured below are available to talk about their presentations and impactful work in the area of heart health.
- Heart disease survivors: Available to share their stories about living with heart disease.
- Vancouver media: Heart experts will be available in Vancouver for on-site or in-studio interviews from October 21 to 24.
CONFERENCE HIGHLIGHTS:
How to end a pandemic – Taking lessons from the fight against HIV/AIDS to heart.
This year’s Canadian Cardiovascular Congress opens on Saturday with a much-anticipated keynote lecture from Vancouver’s own Dr. Julio Montaner, who revolutionized antiretroviral therapy for HIV in the mid-90s, and a decade later pioneered the “Treatment as Prevention¨” (TasP¨) strategy to end the HIV/AIDS pandemic globally. TasP¨ calls for widespread HIV testing, immediate access to antiretroviral therapy and reducing the virus to undetectable levels to prevent progression to AIDS, AIDS-related mortality and transmission of HIV. With its proven success in British Columbia and around the world, TasP¨ is the backbone for the UNAIDS 90-90-90 Target − formally embraced by all UN signatory countries as the road map for the global control of HIV/AIDS by 2030.